Efficacy of B16 melanoma cells exposed in vitro to long-term IFN-α treatment (B16α cells) as a tumor vaccine in mice

Journal of Interferon and Cytokine Research

Volumn 18, Issue 10, 1998, Pages 829-839

  Wu, Tzu Y ^a   Fleischmann Jr , W Robert ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; DRUG EFFECT; DRUG EFFICACY; FEMALE; IMMUNOGENICITY; IMMUNOREGULATION; IMMUNOSTIMULATION; LUNG METASTASIS; MELANOMA; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA;

EID: 0031770534     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1998.18.829     Document Type: Article

References (28)

1. TRAN, R., HAND, P.H., GREINER, J.W., PESTKA, S., and SCHLOM, J. (1988). Enhancement of surface antigen expression on human breast carcinoma cells by recombinant human interferons. J. Interferon Res. 8, 75-88.
2. SOGN, J.A., FINERTY, J.F., HEATH, A.K., SHEN, G.L., and AUSTIN, F.C. (1993). Cancer vaccines: the perspective of the Cancer Immunology Branch, NCI. Ann. NY Acad. Sci. 690, 322-330.
3. FLEISCHMANN, C.M., WU, T.Y., and FLEISCHMANN, W.R., Jr. (1997). B16 melanoma cells exposed in vitro to long-term IfN-α treatment (B16α cells) as activators of tumor immunity in mice. J. Interferon Cytokine Res. 17, 37-43.
4. FLEISCHMANN, C.M., and FLEISCHMANN, W.R., Jr. (1988). Differential antiproliferative activities of IFNs α, β, and γ. kinetics of establishment of resistance to IFNs α and β. J. Biol. Regul. Homeost. Agents 2, 173-185.
5. FLEISCHMANN, C.M., and FLEISCHMANN, W.R., Jr. (1995). Enhanced in vitro macrophage cytotoxicity against interferon-treated B16 melanoma cells. J. Biol. Regul. Homeost. Agents 9, 139-145.
6. FLEISCHMANN, C.M., STANTON, G.J., and FLEISCHMANN, W.R., Jr. (1996). Enhanced in vivo sensitivity of in vitro interferon-treated B16 melanoma cells to CD8 cells and activated macrophages. J. Interferon Cytokine Res. 16, 805-812.
7. BALDWIN, R.W. (1966). Tumor-specific immunity to spontaneous rat tumors. Int. J. Cancer 1, 257-256.
8. KLEIN, G., and KLEIN, E. (1977). Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution. Proc. Natl. Acad. Sci. USA 74, 2121-2125.
9. HEWITT, H.B., BLAKE, E.R., and WALDER, A.S. (1976). A critique of the evidence for active host defense against cancer based on personal studies of 27 murine tumors of spontaneous origin. Br. J. Cancer 33, 241-259.
10. MIDDLE, J.G., and EMBLETON, M.J. (1981). Naturally arising tumors of the inbred WAB/Not rat strain. I. Immunogenicity of transplanted tumors. J. Natl. Cancer Inst. 67, 637-643.
11. FIDLER, I.J. (1973). Selection of successive tumor lines for metastasis. Nature New Biol. 242, 148-149.
12. FIDLER, I.J. (1975). Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res. 35, 218-224.
13. BRUNDA, M.J., SULICH, V., and BELLANTONI, D. (1987). The anti-tumor effect of recombinant interferon alpha or gamma is influenced by tumor location. Int. J. Cancer 40, 807-810.
14. FLEISCHMANN, W.R., Jr., FIELDS, E.E., WANG, J.-L., HUGHES, T.K., and STANTON, G.J. (1991). Modulation of peripheral leukocyte counts in mice by oral administration of interferons. Proc. Soc. Exp. Biol. Med. 197, 424-430.
15. DRANOFF, G., JAFFEE, E., LAZENBY, A., GOLUMBEK, P., LEVISKY, H., BROSE, K., JACKSON, V., HAMADA, H., PARADOLL, D., and MULLIGAN, R.C. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90, 3539-3543.
16. FLEISCHMANN, C.M., STANTON, G.J., and FLEISCHMANN, W.R., Jr. (1994) Enhanced in vivo sensitivity to interferon with in vitro resistant B16 tumor cells in mice. Cancer Immunol. Immunother. 39, 148-154.
17. KOREN, S., and FLEISCHMANN, W.R., Jr. (1986). Quantitation of in vivo potentiation resulting from combined interferon therapy: antitumor effect against B-16 melanoma in mice. J. Interferon Res. 6, 473-482.
18. ZOLLER, M. (1988). IFN-treatment of B16-F1 versus B16-F10: relative impact on nonadaptive and T-cell-mediated immune defense in metastatic spread. Clin. Exp. Metastasis 6, 411-429.
19. KATZ, A., SHULMAN, L.M., PORGADOR, A., REVEL, M., FELDMAN, M., and EISENBACH, L. (1993). Abrogation of B16 melanoma metastases by long-term low-dose interleukin-6 therapy. J. Immunother. 13, 98-109.
20. SHRAYER, D., KONESS, J., KOUTTAB, N., BOGAARS, H., HEARING, V.J., MAIZEL, A., and WANEBO, H.J. (1994). Antitumor effects of polyvalent and monovalent vaccines coupled with interleukin 2 in a metastatic melanoma model. Int. J. Oncol. 4, 1121-1127.
21. KAIDO, T., BANDU, M.-T., MAURY, C., FERRANTINI, M., BELARDELLI, F., and GRESSER, I. (1995). IFN-α1 gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57B1/6 mice. Int. J. Cancer 60, 221-229.
22. SARKAR, S., FLORES, I., DE ROSA, C., OZZELLO, L., RON, Y., and PESTKA, S. (1995). Injection of irradiated B16 melanoma genetically modified to secrete IFN-α causes regression of an established tumor. Int. J. Oncol. 7, 17-24.
23. FERRANTINI, M., PROLETTI, E., SANTODONATO, L., GABRIELE, L., PERETTI, M., PLAVEC, L., MEYER, F., KAIDO, T., GRESSER, I., and BELARDELLI, F. (1993). α1-Interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells. Cancer Res. 53, 1107-1112.
24. GENG, Y., YU, D., BLATT, L.M., and TAYLOR, M.W. (1995). Tumor supressor activity of the human consensus type I interferon gene. Cytokines Mol. Ther. 1, 289-300.
25. ZHANG, J.F., HU, C., GENG, Y., SELM, J., KLEIN, S.B., ORAZI, A., and TAYLOR, M.W. (1996). Treatment of a human breast cancer xenograph with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy. Proc. Natl. Acad. Sci. USA 93, 4513-4518.
26. ZHANG, J.F., HU, C., GENG, Y., BLATT, L.M., and TAYLOR, M.W. (1996). Gene therapy with adenoassociated virus carrying an interferon gene results in tumor growth suppression and regression. Cancer Gene Ther. 3, 31-38.
27. WATANABE, Y., KURIBAYASHI, K., MIYATAKE, S., NISHIHARA, K., NAKAYAMA, E.-I., TANIYAMA, T., and SAKATA, T.-A. (1989). Exogenous expression of mouse interferon-γ cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented antitumor immunity. Proc. Natl. Acad. Sci. USA 86, 9456-9460.
28. DEO, Y., GHEBREMARIAM, H., and CLOYD, M. (1994). Detection and characterization of murine ecotropic recombinant virus in myeloma and hybridoma cells. Hybridoma 13, 69-76.